In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arbutus Biopharma Corp.

www.arbutusbio.com

Latest From Arbutus Biopharma Corp.

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to preempt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Roche Secures Dicerna RNAi Deal For Hepatitis B

Roche has paid $200m up front to get its hands on Dicerna’s RNAi-based drug for chronic hepatitis B in a deal that could be worth around $1.5bn.

Commercial Companies

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration with Galapagos, paying $45m up front.

Deals Business Strategies

Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day

Immunovant is Roivant's 10th drug development-focused firm, progressing RVT-1401, an antibody targeting neonatal Fc receptor (FcRn) in immunoglobulin-mediated autoimmune diseases. Roivant showcased the budding pipeline of its growing family of companies, which now has 12 "vants."

Business Strategies Companies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Tekmira Pharmaceuticals Corp.
  • Inex Pharmaceuticals Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Arbutus Biopharma Corp.
  • Senior Management
  • William H Collier, Pres. & CEO
    Peter Lutwyche , PhD, CTO
    Michael J Sofia, PhD, CSO
    William T Symonds, PharmD, Chief Dev. Officer
  • Contact Info
  • Arbutus Biopharma Corp.
    Phone: (604) 419-3200
    100-8900 Glenlyon Pkwy.
    Burnaby, V5J 5J8
    Canada
UsernamePublicRestriction

Register